Type to search

Diseases Drug Development Oncology Partnerships

Harbour BioMed and Dana-Farber Cancer Institute Collaborate to Advance Novel Biotherapies for Cancer Treatment

Share
Harbour BioMed and Dana-Farber Cancer Institute Collaborate to Advance Novel Biotherapies for Cancer Treatment | Pharmtech Focus

Harbour BioMed (HKEX: 02142) announced today it has entered into a multi-year, multifaceted research collaboration agreement with Dana-Farber Cancer Institute to co-develop novel biotherapies in cancer treatment.

Harbour BioMed scientists and Dana-Farber researchers will be working together to develop novel oncologic drugs, including bispecific antibodies and CAR-T cell products. In recent years, bispecific antibodies and CAR-T cell therapies are both considered as the next-generation solutions in the tumor immunology field. For their ability to engage two different targets, bispecific antibodies are expected to extend the possibilities of monoclonal antibody (mAb) therapeutics, and CAR-T cell therapy is an innovative immunotherapy that uses specially altered T-cells to redirect them to target cancer cells.

This strategic collaboration will leverage Harbour BioMed’s transgenic Harbour Mice® platform with Dana-Farber’s expertise in CAR-T cell development and basic oncology research to generate novel biotherapies.

Harbour BioMed’s antibody technology platforms – Harbour Mice®, which is based on two proprietary transgenic mouse platforms will be utilized to generate human therapeutic antibodies. The platforms have broad potential for generating both conventional as well as next-generation biologics, such as bi- and multi-specifics, CAR-Ts or VH domain-derived products that are fully human, affinity matured with excellent solubility and developability.

“We are delighted to initiate this collaboration with Harbour BioMed. The complementary technology and expertise between Harbour and DFCI will dramatically shorten the interval from novel discovery to developing optimized antibody and cellular therapies for clinical translation,” said Dr. Eric SmithLaboratory Principal Investigator & Director of Translational Research for Immune Effector Cell Therapies at Dana-Farber Cancer Institute.

“The collaboration with world renowned Dana-Farber Cancer Institute demonstrates HBM’s commitment to developing novel medicines and fostering fast-track innovative research. I believe this collaboration will be ultimately translated into better treatments for cancer patients,” said Jingsong Wang, Founder, Chairman & Chief Executive Officer of HBM. 

Tags:

People in this post:

Next Up